Abeona Therapeutics (ABEO) Operating Leases (2019 - 2026)

Abeona Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 6.47% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $3.8 million, a 6.47% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, up 24.74% from the prior year.
• Operating Leases slipped to $3.8 million in Q1 2026 per ABEO's latest filing, from $4.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $9.1 million in Q1 2022 and bottomed at $3.0 million in Q2 2024.
• The 5-year median for Operating Leases is $4.1 million (2025), against an average of $5.0 million.
• Across the five-year window, Operating Leases soared 86.72% in 2022 and plunged 51.25% in 2023, its largest moves.
• Year by year, Operating Leases stood at $5.9 million in 2022, then declined by 24.8% to $4.4 million in 2023, then retreated by 25.9% to $3.3 million in 2024, then advanced by 24.74% to $4.1 million in 2025, then slipped by 6.27% to $3.8 million in 2026.
• Per Business Quant, the three latest ABEO Operating Leases figures stand at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $4.3 million (Q3 2025).